GeoVax Labs (NASDAQ:GOVX) Releases Earnings Results, Beats Expectations By $0.14 EPS

Posted by Lauren Steadman on May 3rd, 2025

GeoVax Labs (NASDAQ:GOVX – Get Free Report) posted its earnings results on Thursday. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.14, Zacks reports. The business had revenue of $1.64 million during the quarter, compared to the consensus estimate of $0.75 million.

GeoVax Labs Stock Performance

GOVX opened at $1.01 on Friday. The company’s 50-day simple moving average is $1.21 and its two-hundred day simple moving average is $1.86. GeoVax Labs has a 52-week low of $0.73 and a 52-week high of $11.18. The stock has a market capitalization of $13.98 million, a P/E ratio of -0.18 and a beta of 3.70.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GOVX. Alliance Global Partners cut their target price on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. D. Boral Capital lowered their target price on shares of GeoVax Labs from $14.00 to $9.00 and set a “buy” rating for the company in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and an average price target of $11.10.

View Our Latest Analysis on GeoVax Labs

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.